Citadel Advisors’s Applied Genetic Technologies Corporation AGTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-18,900
| Closed | -$15K | – | 14103 |
|
|
2022
Q2 | $15K | Buy |
18,900
+5,900
| +45% | +$5.26K | ﹤0.01% | 12507 |
|
|
2022
Q1 | $14K | Buy |
+13,000
| New | +$23.6K | ﹤0.01% | 13336 |
|
|
2021
Q4 | – | Sell |
-51,700
| Closed | -$156K | – | 15259 |
|
|
2021
Q3 | $156K | Sell |
51,700
-54,300
| -51% | -$193K | ﹤0.01% | 12337 |
|
|
2021
Q2 | $414K | Sell |
106,000
-35,800
| -25% | -$148K | ﹤0.01% | 10488 |
|
|
2021
Q1 | $719K | Buy |
141,800
+96,600
| +214% | +$501K | ﹤0.01% | 8881 |
|
|
2020
Q4 | $185K | Sell |
45,200
-13,300
| -23% | -$65.3K | ﹤0.01% | 9799 |
|
|
2020
Q3 | $284K | Buy |
58,500
+22,600
| +63% | +$123K | ﹤0.01% | 8228 |
|
|
2020
Q2 | $199K | Buy |
35,900
+7,500
| +26% | +$34.4K | ﹤0.01% | 8532 |
|
|
2020
Q1 | $93K | Buy |
28,400
+6,700
| +31% | +$35.3K | ﹤0.01% | 8679 |
|
|
2019
Q4 | $98K | Buy |
21,700
+9,700
| +81% | +$30.7K | ﹤0.01% | 8561 |
|
|
2019
Q3 | $50K | Sell |
12,000
-2,300
| -16% | -$8.3K | ﹤0.01% | 8706 |
|
|
2019
Q2 | $54K | Sell |
14,300
-8,700
| -38% | -$35.7K | ﹤0.01% | 8708 |
|
|
2019
Q1 | $96K | Buy |
23,000
+11,500
| +100% | +$40.2K | ﹤0.01% | 8575 |
|
|
2018
Q4 | $29K | Buy |
+11,500
| New | +$67.4K | ﹤0.01% | 8633 |
|
|
2017
Q3 | – | Sell |
-10,200
| Closed | -$52K | – | 8224 |
|
|
2017
Q2 | $52K | Buy |
+10,200
| New | +$57.3K | ﹤0.01% | 7084 |
|
Citadel Advisors's AGTC Position: Q4 2022 in Review
Citadel Advisors sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2022, closing a stake of 423,709 shares — an estimated $115K sold.
Citadel Advisors first reported a position in AGTC in Q1 2015 and held it in 15 quarters. The position peaked at $1.14M in Q1 2016. 0 funds tracked by Wall St. Rank hold AGTC as of Q4 2022.
- Citadel Advisors reported no remaining Applied Genetic Technologies Corporation position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 423,709 Applied Genetic Technologies Corporation shares in Q4 2022, an estimated $115K.
- Citadel Advisors first reported a position in Applied Genetic Technologies Corporation in Q1 2015 and held it in 15 quarters.
- Citadel Advisors's Applied Genetic Technologies Corporation position peaked at $1.14M in Q1 2016.
- 0 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.